Using cutting-edge technology, a team of top doctors will test multiple treatments on a patient’s cancer cells to determine which would be most effective.
Dr. Jennifer Knox
Dr. Elizabeth Jaffee
Pancreatic cancer is the third leading cause of cancer-related death in both the United States and Canada
The five-year survival rate for pancreatic cancer is around 10% in the United States and 8% in Canada
Dr. Jennifer Knox and her team at Princess Margaret Cancer Centre are working to change that with a new research project called PASS-01, which aims to broaden our understanding of this disease to ultimately give patients their greatest chance at a longer life.
Doctors currently don’t know enough about the different subtypes of pancreatic cancer to determine which of the two leading chemotherapy treatments might actually help an individual patient.
Through the use of genomic analysis and organoid technology, PASS-01 aims to determine potential predictors of patient response to chemotherapy. As well, PASS-01 will explore the identification of specific biomarkers that indicate which patients respond better to one treatment or another.
|Project Length||4 years|
|Goal||Our goal is to give patients with advanced pancreatic cancer the greatest possibility of a longer life through personalized medicine. To do this we need to increase foundational understanding about the different subtypes of pancreatic cancer and the efficacy of potential biomarkers to help inform treatment plans for future patients.|
|Research Type||Exploratory research|